Voronoi, Inc. engages in the manufacture of novel kinase inhibitors and target protein degrader drugs. The company was founded on February 24, 2015 and is headquartered in Incheon, South Korea.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company